Q4 and FY 2022 Results

March 7, 2023





Trademarks herein are held by their respective owners.

Cautionary Note Regarding Presentation Information



This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue," "could," "intend," "target," "predict," or the negative versions of those words or other comparable words or expressions, although not all forward-looking statements contain these identifying words or expressions. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements include statements regarding the promise and potential impact of our preclinical or clinical trial data, including without limitation the timing and results of any clinical trials or readouts, the timing or results of any lovestigational New Drug applications and NDA submissions, including the resubmission of the NDA for arimoclomol, communications with the FDA, the potential uses or benefits of arimoclomol, KP1077, SDX or any other product candidates for any specific disease indication or at any dosage, the potential benefits of any of Zevra's product candidates, the success or timing of the launch or commercialization of AZSTARYS[®] or any other products or related sales milestones, the sufficiency of cash to fund operations, expected net revenue from the French EAP program, our plans or ability to seek funding, our plans with respect to our share repurchase program, and our strategic and product development objectives. These forward-looking statements are based on information currently available to Zevra and its current plans or expected net revenues expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2022, and Zevra's other impo

While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to this presentation.

This presentation also may contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Agenda





Strategic Overview, 2022 Highlights & Program Updates

Richard W. Pascoe, CEO

AZSTARYS[®] Commercial Update, 2022 Financial Results & 2023 Financial Guidance

R. LaDuane Clifton, CFO, Secretary & Treasurer

Upcoming Milestones & 2023 Outlook

Richard W. Pascoe, CEO

Q&A

Richard W. Pascoe, CEO R. LaDuane Clifton, CFO, Secretary & Treasurer Travis C. Mickle, President & Co-Founder Christal Mickle, Chief Product Development Officer Joshua Schafer, Chief Commercial Officer & EVP, BD

EVRA

We are Zevra



Nimble and focused rare disease company with track record of success in overcoming drug development & regulatory challenges Leveraging unique insights and regulatory strategies to forge pathways to success for transformational rare disease therapies

R		
⊈	jΖ	1
-		-

Well positioned for success with robust pipeline, worldclass management and board and strong balance sheet



Our Strategic Evolution

Responding to market dynamics, stakeholder demand, and changing technologies and circumstances to ensure **relevance, progress and prosperity**

Significant Value-Creation Opportunity in Rare Disease for Patients and Shareholders





Unique partnerships with patient communities



Longer market exclusivity and less generic competition



Lower cost of R&D



Regulatory and financial incentives



Shorter development timelines & smaller studies



Small patient population served by specialist clinicians can be addressed with in-house commercial team

Why Zevra Therapeutics?

Zevra, Greek for zebra, is the internationally recognized symbol for the rare disease community





Positioned for Success



Strategic focus on rare diseases	 Build a highly differentiated pipeline of development assets with multiple clinical and regulatory milestones Focus on high-value areas with significant unmet needs in rare disease with potential to internally commercialize
Arimoclomol: treatment of Niemann-Pick disease Type C (NPC)	 NDA-stage drug candidate being developed for the treatment of NPC "Capital efficient" financial structure; potential for positive cash flow; no shareholder dilution NDA resubmission expected as early as Q3 2023; potential Zevra commercial candidate
KP1077: treatment of idiopathic hypersomnia (IH) and narcolepsy	 High-value opportunity with significant unmet need Initiated IH Phase 2 Trial in December 2022 Initiate Narcolepsy Phase 3 Trial post IH Phase 2 results
Other product opportunities	 Leverage prodrug platform to internally develop product candidates with significant potential value Business development activities focused on complimentary clinical-stage rare disease assets
AZSTARYS [®] license	 Expanding launch of AZSTARYS provides ongoing revenue potential from royalties and milestones
Strong balance sheet	 Cash, cash equivalents and investments of \$102.9M as of December 31, 2022 Strong cash position supports development plan and other opportunities Based on operating forecast, cash runway expected to extend into 2026

2022 Highlights



Arimoclomol for Niemann-Pick Type C	KP1077 for Rare Sleep Disorders	Financial	Leadership Appointments
 5/15: Arimoclomol acquisition Completion of 4-year safety trial Ongoing collaborative dialogue and periodic meetings with the FDA 	 4/19: Phase 1 SDX cardiovascular safety trial initiation 5/5: IND submitted for Phase 2 study in idiopathic hypersomnia 9/28: Phase 1 positive topline cardiovascular trial data 11/18: Orphan drug designation in IH 12/21: Phase 2 trial initiation in idiopathic hypersomnia 	 3/16: One-time fee of \$1.975M from Corium following FDA approval of ADLARITY[®] Net revenue of \$10.5M for full year 2022 Cash, cash equivalents and investments of \$102.9M as of Dec. 31, 2022 Available capital expected to extend cash runway into 2026 	 11/28: Christopher Posner appointed independent director 8/9: Nichol Ochsner appointed VP, IR and Corp Comms

Q4 2022 and Recent Highlights

EVRA



Financial

Net revenue of **\$2.3M** for Q4

Ended the year with **\$102.9 million** of capital available on the balance sheet

Leadership Appointment

January 9, 2023

Rare Sleep Disorders November 18, 2022 Orphan Drug Designation received for treatment of IH	Board Chairman	Corporate February 22, 2023 Company renamed Zevra Therapeutics, Inc.	Corporate February 28, 2023 Joined NORD Corporate Council
Initiation of Phase 2 study in IH KP1077 for Rare Sleep Disorders December 21, 2022	Daniel Gallo, Ph.D. <i>SVP Medical Affairs &</i> <i>Advocacy</i> Abbi Maher, J.D. <i>VP of Legal Affairs</i> Leadership Appointment January 31, 2023	Interim analysis of four safety study presented WORLDSymposium s arimoclomol may redu disease progression Arimoclomol for Niem Pick Disease Type C February 24, 202	d at suggest uce Corporate March 1, 2023

KP1077 for

World Class Leadership Team and Board



Decades of R&D and Commercialization Experience Driving **Excellence in Rare Disease**



Richard Pascoe CEO



Travis Mickle, Ph.D. President & Co-Founder



R. LaDuane Clifton Sven Guenther, Ph.D. CFO, Secretary & Treasurer Chief Scientific Officer





Christal Mickle Chief Product Development Officer & Co-Founder

Joshua Schafer Chief Commercial Officer & EVP of BD

Board of Directors

Matthew R. Plooster Chairman

Richard Pascoe

Travis Mickle, Ph.D.

Tamara A. (Seymour) Favorito

Joseph B. Saluri

David S. Tierney, M.D.

Christopher Posner

11



ARIMOCLOMOL

For the Treatment of Niemann-Pick Disease Type C (NPC)

Arimoclomol – Innovative Product for a High Unmet Need



FIRST-IN-CLASS, ORAL TREATMENT INTENDED FOR NPC

- Capsule formulation designed to be swallowed whole, opened to allow contents to be mixed with soft foods/liquids or delivered through a gastric feeding tube
- Nonclinical and clinical evidence demonstrated significantly improved lysosomal and cellular function with arimoclomol treatment



EXTENSIVELY RESEARCHED

- Studied in ten Phase 1, four Phase 2, and three Phase 2/3 trials
- No significant safety findings identified to date (500+ patients treated)
- Positive efficacy results from NPC trial (NPC-002) and Phase 2 trial in Gaucher Disease (GD), both of which are lysosomal storage disorders



ZEVRA

THERAPEUTICS

- Orphan Drug Designation for NPC in U.S. and EU
- Fast-Track Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation from the FDA for NPC
- Eligible to receive Rare Pediatric Disease Priority Review Voucher if approved by FDA

Zevra expects to resubmit the NDA for arimoclomol in NPC as early as Q3 2023

Near-Term Opportunity to Commercialize and Retain Full Market Value



Launch arimoclomol with a small, focused commercialization effort which can be foundation for future rare disease products, including KP1077



Patient advocacy relationships support adoption



SDX PRODUCT CANDIDATE: KP1077

For the Treatment of Idiopathic Hypersomnia (IH)

KP1077 – Multiple Clinical Programs Targeting Rare Sleep Indications



KP1077 Represents a Potential "Portfolio in a Pill" Opportunity

IDIOPATHIC HYPERSOMNIA	NARCOLEPSY
 Lead KP1077 indication 	 Second KP1077 indication would allow Zevra
 Investigational New Drug (IND) application	to address two rare sleep indications that are
cleared by FDA	underserved by currently available medications
 Ongoing phase 2 clinical trial was initiated in	 Evaluate the potential to initiate narcolepsy
December 2022	Phase 3 trial based on IH phase 2 results
 Interim data from Phase 2 clinical trial	 Seek to leverage key data points from IH
expected as early as Q3 2023	program to expedite narcolepsy development
 Top-line data expected by EOY 2023 	

IH Phase 2 results may support advancement into Phase 3 in narcolepsy




AZSTARYS[®] Commercialization Update

d-Methylphenidate Prodrug Product for the Treatment of ADHD

AZSTARYS[®] Prescription Trends Are Encouraging



Potential to achieve one or more sales milestones based on current trend



¹ Source: Symphony Health, MetysTM Version 5.8.1, 2023

AZSTARYS[®] Provides a Foundation



Royalties from legacy develop/out-license model may not be a strong growth driver in short or medium term

	Quarterly TRx ¹	Cumulative TRx	Actual Royalties
Q3 2021	497	497	\$0.03M
Q4 2021	5,189	5,686	\$0.06M
Q1 2022	8,710	14,396	\$0.08M
Q2 2022	15,130	29,526	\$0.13M
Q3 2022	25,418	54,944	\$0.24M
Q4 2022	53,811	108,755	\$0.40M
Q1 2023 (thru Feb 24)	55,272	164,027	TBD

- Trend line improvement noted in Q3 2022, with coverage at three largest PBMs and ~175 field reps in the field (as reported by Corium, Inc.)
- Potential for FY 2023 to benefit from added focus on adult ADHD market
- Royalties are meaningful, but modest
- Sales milestones, if achieved, improve return



FINANCIAL UPDATE

Financial Position is a Source of Strength



Q4 and FY 2022 Results:

- Net Revenue:
 - Q4 2022 was \$2.3M; FY 2022 was \$10.5M, derived primarily from the French EAP program, royalties and consulting service fees
- Net Loss Attributable to Common Stockholders:
 - Q4 2022 was (\$9.0M), or (\$0.26) per basic and diluted share, driven primarily by R&D expense of \$6.4M, and G&A expense of \$5.1M, partially offset by net revenue of \$2.3M
 - FY 2022 was (\$41.5M), or (\$1.20) per basic and diluted share, driven primarily by R&D expense of \$19.6M, G&A expense of \$15.3M, and a one-time non-cash charge of \$17.7M for in-process R&D from the arimoclomol acquisition, partially offset by net revenue of \$10.5M
 - Non-GAAP FY 2022 net loss excluding the one-time non-cash charge of \$17.7M was (\$23.9M), or (\$0.69) per basic and diluted share

Balance Sheet as of Dec 31, 2022:

- Cash, cash equivalents and investments was \$102.9M, a decrease of \$4.5M vs. Sep 30, 2022
- Common shares outstanding of 34,540,304, fully diluted shares outstanding of 47,088,184

2023 Financial Guidance



Cash balance remains strong, with potential to realize milestone revenue


- Available cash, cash equivalents and investments expected to extend cash runway into 2026
 - Current operating plan includes the expected reimbursements from the French arimoclomol EAP, the full development of KP1077 through NDA submission and potential PDUFA, as well as investments needed to prepare for the potential U.S. launch of arimoclomol, if approved.
- Based on current prescription trend for AZSTARYS[®], we expect to achieve at least the first net sales milestone under the license agreement with Commave Therapeutics, SA
- Net revenue from French EAP program expected to continue at approximately \$2.0M per quarter throughout FY 2023 and beyond
- R&D investments for KP1077 will be higher during FY 2023 due to the ongoing Phase 2 trial, and the
 preparation for the potential initiation of a Phase 3 Trial.



Outlook for 2023 and Beyond

Multiple Growth Catalysts in 2023







Q&A

Thank You.



